Literature Summary
Pylopass® may influence UBT (Urea Breath Test) values, an indicator for Helicobacter pylori.
(Mehling H et al., 2013)

Studies indicate Pylopass® can adhere to specific gastric bacteria and influence UBT values, supporting its role in microbiome research and functional food development.
This section summarizes research directions only and does not imply any health claims.
Dosage Forms

Capsules

tablets

powder sachets

functional beverages
FAQ
Pylopass® is a patented probiotic ingredient scientifically known as Lactobacillus reuteri DSM 17648. Developed in Germany and manufactured in France, it is a precision targeting strain designed for gastric health formulations.
Pylopass® possesses unique adhesion properties and target recognition capabilities. It can adhere to specific bacterial groups in the stomach and is considered a precision targeting strain for managing gastric microecological balance.
No refrigeration is required. Pylopass® features excellent room temperature stability and can be stored at ambient temperatures, which facilitates mass production in the food industry and reduces cold chain logistics costs.
UBT (Urea Breath Test) is a primary indicator for detecting Helicobacter pylori. Research shows that supplementing with Pylopass® can influence UBT values, helping to maintain a healthy gastric environment.
It is especially suitable for individuals who frequently eat out, have a fast-paced lifestyle, maintain irregular eating habits, or prioritize daily gastric health maintenance.
It offers high formulation flexibility and is suitable for various product formats, including capsules, tablets, powder sachets, and functional beverages.
Yes, Pylopass® has passed safety evaluations from US GRAS and EU QPS, meeting the compliance requirements of major international markets.
It complies with international quality systems, including ISO 22000 standards, and has obtained Halal and non-GMO (non-genetically modified organism) certifications.
Yes, the sources cite several international studies (e.g., Mehling H et al., 2013) confirming that non-viable Pylopass® is a novel approach for controlling Helicobacter pylori in humans.
It operates by using physical surface structures to bind with specific bacteria; therefore, it does not rely on viability to perform its target recognition role in the gastrointestinal tract.